FY2028 EPS Estimates for Travere Therapeutics, Inc. (NASDAQ:TVTX) Decreased by Analyst

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Research analysts at HC Wainwright decreased their FY2028 earnings per share estimates for Travere Therapeutics in a research report issued on Wednesday, April 24th. HC Wainwright analyst E. Arce now anticipates that the company will earn $4.29 per share for the year, down from their prior estimate of $4.66. HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share.

Several other research firms have also commented on TVTX. Wells Fargo & Company increased their target price on Travere Therapeutics from $8.00 to $9.00 and gave the company an “equal weight” rating in a report on Friday, February 16th. Wedbush reissued an “outperform” rating and issued a $13.00 target price on shares of Travere Therapeutics in a report on Wednesday, April 17th. Piper Sandler increased their target price on Travere Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Thursday, January 18th. Finally, Guggenheim reissued a “neutral” rating on shares of Travere Therapeutics in a report on Wednesday, March 27th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Travere Therapeutics Stock Performance

NASDAQ:TVTX opened at $5.26 on Thursday. The firm has a market capitalization of $400.33 million, a PE ratio of -3.27 and a beta of 0.58. The business’s fifty day moving average price is $7.28 and its 200 day moving average price is $7.65. The company has a debt-to-equity ratio of 1.88, a current ratio of 3.47 and a quick ratio of 3.41. Travere Therapeutics has a 12 month low of $5.12 and a 12 month high of $22.75.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.27) by $0.11. The business had revenue of $45.06 million for the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative return on equity of 177.97% and a negative net margin of 56.02%.

Institutional Investors Weigh In On Travere Therapeutics

Several hedge funds have recently made changes to their positions in TVTX. SG Americas Securities LLC acquired a new stake in Travere Therapeutics in the third quarter valued at about $1,179,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Travere Therapeutics by 32.0% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,511 shares of the company’s stock valued at $148,000 after purchasing an additional 4,007 shares during the period. Emerald Advisers LLC lifted its position in Travere Therapeutics by 64.9% in the third quarter. Emerald Advisers LLC now owns 1,060,302 shares of the company’s stock valued at $9,479,000 after purchasing an additional 417,250 shares during the period. Emerald Mutual Fund Advisers Trust lifted its position in Travere Therapeutics by 44.4% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 764,603 shares of the company’s stock valued at $6,836,000 after purchasing an additional 235,085 shares during the period. Finally, Cheyne Capital Management UK LLP acquired a new stake in Travere Therapeutics in the third quarter valued at about $234,000.

Insiders Place Their Bets

In other news, CEO Eric M. Dube sold 19,122 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.70, for a total transaction of $166,361.40. Following the completion of the sale, the chief executive officer now owns 350,600 shares in the company, valued at $3,050,220. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Eric M. Dube sold 19,122 shares of the stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $8.70, for a total transaction of $166,361.40. Following the completion of the sale, the chief executive officer now owns 350,600 shares in the company, valued at $3,050,220. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Christopher R. Cline sold 3,818 shares of the stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $8.53, for a total transaction of $32,567.54. Following the sale, the chief financial officer now owns 70,903 shares of the company’s stock, valued at approximately $604,802.59. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,773 shares of company stock valued at $300,625. 3.75% of the stock is currently owned by insiders.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.